Harpoon Therapeutics (NASDAQ:HARP) Price Target Lowered to $40.00 at Canaccord Genuity Group

Harpoon Therapeutics (NASDAQ:HARP) had its price objective cut by Canaccord Genuity Group from $80.00 to $40.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Harpoon Therapeutics in a research report on Thursday, August 10th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Harpoon Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Harpoon Therapeutics Stock Down 18.3 %

Shares of NASDAQ HARP traded down $1.20 during trading on Thursday, reaching $5.34. The company had a trading volume of 151,619 shares, compared to its average volume of 33,093. Harpoon Therapeutics has a 12-month low of $4.74 and a 12-month high of $33.55. The business’s 50-day moving average is $8.16 and its 200 day moving average is $7.41. The stock has a market cap of $20.70 million, a PE ratio of -0.45 and a beta of 1.48.

Harpoon Therapeutics (NASDAQ:HARP) last announced its quarterly earnings results on Wednesday, August 9th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.30) by $4.60. The company had revenue of $20.22 million for the quarter, compared to analysts’ expectations of $9.19 million. Harpoon Therapeutics had a negative net margin of 86.73% and a negative return on equity of 620.00%. On average, analysts anticipate that Harpoon Therapeutics will post -7.27 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA raised its stake in Harpoon Therapeutics by 571.5% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 12,986 shares of the company’s stock valued at $25,000 after buying an additional 11,052 shares during the last quarter. Delphia USA Inc. purchased a new stake in Harpoon Therapeutics during the first quarter valued at $57,000. Sequoia Financial Advisors LLC bought a new position in Harpoon Therapeutics in the first quarter valued at about $66,000. Two Sigma Investments LP boosted its position in Harpoon Therapeutics by 73.6% in the third quarter. Two Sigma Investments LP now owns 33,361 shares of the company’s stock worth $32,000 after purchasing an additional 14,149 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Harpoon Therapeutics by 8.7% during the 2nd quarter. Renaissance Technologies LLC now owns 213,600 shares of the company’s stock valued at $152,000 after purchasing an additional 17,180 shares during the last quarter. 74.01% of the stock is owned by hedge funds and other institutional investors.

About Harpoon Therapeutics

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma.